Compare Incyte Corporation (INCY) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ross Stores, Inc. — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Ross Stores, Inc. trades at $222.07 (market cap $71.94B). The key difference: Ross Stores, Inc. is far larger — about 3.1× Incyte Corporation's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Ross Stores, Inc. for 48 Days on average.
| INCY | ROST | |
|---|---|---|
Market Cap | $22.85B | $71.94B |
Volume | 1,927,029 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $255.23 |
52-Week Low | $83.80 | $147.71 |
Typical Hold Time | 33 Days | 48 Days |
Enterprise Value | $18.35B | $72.39B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Ross Stores (ROST) trades at $222.41, down 1.38% on the day, as technical indicators signal bearish momentum despite strong fundamental performance. The company continues to deliver robust earnings beats with Q2 2026 EPS of $2.66 exceeding expectations of $1.95, while maintaining impressive profitability metrics including 42.63% ROE and 10.85% net income margin. Recent news highlights store expansion initiatives and strong closeout supply positioning the off-price retailer to capture value-conscious consumer demand.
With analyst consensus pointing to 23% upside to the $274.14 price target and 64% buy ratings, ROST presents a compelling growth opportunity despite near-term technical weakness. Key risks include competitive pressures in discount retail and execution challenges in store expansion, but strong cash flow generation and disciplined inventory management support the bullish fundamental case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
